-
admin
Posts
SK hynix Announces 4Q24 Financial Results
Revenues for 2024 at 66.1930 trillion won, operating profit at 23.4673 trillion won, net profit at 19.7969 trillion won Revenues for Q4 at 19.7670 trillion...
Health In Tech Announces Innovative Collaboration with MARPAI and Vitable DPC to Offer Competitive Quotes in Enhanced Self-Funded Solutions
STUART, Fla., Jan. 23, 2025 /PRNewswire/ — Health In Tech, an Insurtech platform company backed by third-party AI technology, is thrilled to announce a new strategic...
Bright Scholar Schedules Unaudited Financial Results for the First Quarter of Fiscal 2025 Ended November 30, 2024
CAMBRIDGE, England and FOSHAN, China, Jan. 23, 2025 /PRNewswire/ — Bright Scholar Education Holdings Limited (“Bright Scholar,” the “Company,” “we” or “our”) (NYSE: BEDU), a...
Ice Cream Global Forecast Report 2025: Market to Reach $125.62 Billion in 2033 from $80.03 Billion in 2024, with a CAGR of 5.14% from 2025 to 2033
Dublin, Jan. 22, 2025 (GLOBE NEWSWIRE) — The “Ice Cream Market Global Report by Products, Category, Type, Flavor, Distribution Channel, Countries and Company Analysis 2025-2033”...
1-Decanol Market Analysis Report 2025-2034: Kuala Lumpur Kepong Berhad, Sasol Limited, Musim Mas Group, Emery Oleochemicals, and BASF Lead the Competition
Dublin, Jan. 22, 2025 (GLOBE NEWSWIRE) — The “1-Decanol Market Report 2025” report has been added to ResearchAndMarkets.com’s offering. This 1-Decanol market report covers market...
Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America
REHOVOT, Israel and HOBOKEN, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of...
Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study
–PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy on gait deficit improvement in people with Multiple Sclerosis– –Statistically significant...
Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer
Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products, including BTK inhibitor ibrutinib SAN FRANCISCO, Jan. 22,...
OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding
LONDON and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
Company Announcement Net sales of DARZALEX® in 2024 totaled USD 11,670 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal...
